BMY 25282
BMY 25282 (BL 6782) is a mitomycin C (MMC) analog. BMY 25282 catalyzes oxygen activation in hepatocytes. BMY 25282 overcomes MMC tolerance in colon cancer cells and mouse models of colon cancer. BMY 25282 inhibits tumor growth in mouse models of leukemia and melanoma. BMY 25282 can be used in research on cancers such as leukemia, melanoma, and colon cancer.
For research use only. We do not sell to patients.
- CAS No.: 88949-01-3
- Formula: C18H23N5O5
- Molecular Weight:389.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Chemical Information
-
CAS No. 88949-01-3
-
Molecular Weight 389.41
-
Formula C18H23N5O5
-
SMILES
CO[C@]12N(C[C@H]3[C@@H]2N3)C4=C(C(C(/N=C/N(C)C)=C(C)C4=O)=O)[C@H]1COC(N)=O
-
Synonyms
BL 6782
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Silva JM, et al. Contrasting molecular cytotoxic mechanisms of mitomycin C and its two analogs, BMY 25282 and BMY 25067, in isolated rat hepatocytes. Biochem Pharmacol. 1993 Jun 9;45(11):2303-9. [Content Brief]
[2]. Willson JK, et al. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells. Cancer Res. 1985 Nov;45(11 Pt 1):5281-6. [Content Brief]
[3]. Bradner WT, et al. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative. Cancer Res. 1985 Dec;45(12 Pt 1):6475-81. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BMY 25282 Related Classifications
HY-105361 Related Classifications
Powered by Bioz